Evidence map›Paper›PMID 41417112›Full record

ArticleJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry2026

Looking backward to move forward: a chemist's perspective on the future of radiopharmaceuticals.

Stacey E Rudd

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pharmaceuticals (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Stacey E RuddSchool of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Melbourne, VIC, Australia. stacey.rudd@unimelb.edu.au.ORCID http://orcid.org/0000-0001-9996-8561

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear medicine has existed since the 1940s, but the clinical approval of a handful of new radiopharmaceutical agents in the last few years has thrust the field into the spotlight of modern cancer research. Now that radiopharmaceuticals have caught everyone's attention, what are the future directions in this rapidly growing area? This commentary highlights some of the field's successes and failures over the last few decades, explores emerging ideas for the next steps in radiopharmaceutical development, and ponders whether we are ready to revisit old ideas using a modern twist.

Indexed as

NeoplasmsRadiopharmaceuticalsHumansRadiopharmaceuticalsMetal radionuclidesNuclear medicineRadiochemistryRadioimmunotherapyTheranostics

Identifiers

PMID41417112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.